◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksC › CUPR

Cuprina Holdings (Cayman) Limited (CUPR) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Instruments & Supplies · DATA UPDATED 2026-09-11

Cuprina Holdings (Cayman) Limited (CUPR) operates in the Medical Instruments & Supplies industry and is headquartered in Singapore, Singapore with about 10 employees. Its market capitalization is roughly $8 million. In the fiscal year ended 2025-12-31, CUPR reported SGD 0M in revenue and (SGD 5M) in net income.

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds.

Interactive charts & full statements → Open the CUPR valuation workbench →

CUPR Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueSGD 0MSGD 0MSGD 0MSGD 0M
Gross ProfitSGD 0MSGD 0MSGD 0MSGD 0M
Operating Income (EBIT)(SGD 5M)(SGD 2M)(SGD 1M)(SGD 1M)
Net Income(SGD 5M)(SGD 2M)(SGD 1M)(SGD 1M)

SGD; SGDM / SGDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CUPR Free Cash Flow History

CUPR Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsSGD 8MSGD 2MSGD 2MSGD 1M
Total LiabilitiesSGD 3MSGD 6MSGD 4MSGD 3M

SGD; SGDM / SGDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CUPR viewer.

Other Companies in Medical Instruments & Supplies

← CUPIDAll “C” companiesCURA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.